--- title: "The Oral GLP-1 Pill Race Widens: Conveglipron (HDM1002) Joins Orforglipron in the Hunt for a Needle-Free Weight-Loss Drug — June 15, 2026 | PepTracker Pro Blog" description: "Conveglipron (HDM1002) is an oral, once-daily small-molecule GLP-1 receptor agonist from Huadong Medicine now in Phase 2 for obesity and Phase 3 for type 2 diabetes. Here's how the GLP-1 'pill' race is shaping up against orforglipron and danuglipron — and why an oral small molecule is not the same thing as a peptide." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "The Oral GLP-1 Pill Race Widens: Conveglipron (HDM1002) Joins Orforglipron in the Hunt for a Needle-Free Weight-Loss Drug — June 15, 2026", "description": "Conveglipron (HDM1002) is an oral, once-daily small-molecule GLP-1 receptor agonist from Huadong Medicine now in Phase 2 for obesity and Phase 3 for type 2 diabetes. Here's how the GLP-1 'pill' race is shaping up against orforglipron and danuglipron — and why an oral small molecule is not the same thing as a peptide.", "datePublished": "2026-06-15", "dateModified": "2026-06-15", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/blog/oral-glp1-pill-race-conveglipron-hdm1002-vs-orforglipron-danuglipron-june-15-2026" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://peptrackerpro.com/blog" }, { "@type": "ListItem", "position": 3, "name": "The Oral GLP-1 Pill Race Widens: Conveglipron (HDM1002) Joins Orforglipron in the Hunt for a Needle-Free Weight-Loss Drug — June 15, 2026", "item": "https://peptrackerpro.com/blog/oral-glp1-pill-race-conveglipron-hdm1002-vs-orforglipron-danuglipron-june-15-2026" } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Blog](/blog)/ The Oral GLP-1 Pill Race Widens: Conveglipron (HDM1002) Joins Orforglipron in the Hunt for a Needle-Free Weight-Loss Drug — June 15, 2026 Research & Compounds Research & Compounds # The Oral GLP-1 Pill Race Widens: Conveglipron (HDM1002) Joins Orforglipron in the Hunt for a Needle-Free Weight-Loss Drug — June 15, 2026 PepTracker Pro Research Team June 15, 2026 9 min read ## Table of Contents - [Why everyone wants a GLP-1 in a pill](#section-0) - [What conveglipron (HDM1002) actually is](#section-1) - [What the human data show so far](#section-2) - [Where it sits in the oral GLP-1 race](#section-3) - [Small molecule does not mean peptide — and 'in trials' does not mean 'available'](#section-4) - [What to watch next](#section-5) ## Why everyone wants a GLP-1 in a pill GLP-1 receptor agonists like semaglutide (Wegovy/Ozempic) and the dual agonist tirzepatide (Mounjaro/Zepbound) reshaped obesity and diabetes care — but they share a practical limitation: they are injectable peptides. Peptides are fragile, complex to manufacture at the scale of hundreds of millions of patients, and most are delivered by injection. An oral small molecule that hits the same GLP-1 receptor would sidestep all of that: pills are cheaper to make, easier to ship and store, and far more acceptable to people who don't want a weekly shot. That is why the 'oral GLP-1' race has become one of the most closely watched contests in metabolic medicine — and why a new entrant, conveglipron, is worth understanding. ## What conveglipron (HDM1002) actually is Conveglipron, still widely known by its developmental code HDM1002, is an investigational oral, once-daily small-molecule GLP-1 receptor agonist developed by China-based Huadong Medicine. Chemically it is a selective, potent full agonist of the GLP-1 receptor — the same target as semaglutide — but it is a small molecule, not a peptide. That distinction matters: small molecules can often be made by conventional chemical synthesis rather than the specialized peptide manufacturing that injectables require, which is precisely the cost-and-scale advantage developers are chasing. Conveglipron is taken as a daily pill and is being developed for both obesity and type 2 diabetes. ## What the human data show so far Conveglipron has moved beyond animal studies into published human trials. A first-in-human single-ascending-dose study in healthy volunteers (Diabetes, Obesity & Metabolism, 2025) established acceptable safety, tolerability, and pharmacokinetics. A randomized, double-blind, placebo-controlled Phase 1b study in 60 Chinese adults with overweight or obesity (published in Obesity, 2026) then tested multiple ascending doses from 50 to 400 mg over 28 days. Participants in the higher-dose groups lost roughly 4.9% to 6.8% of body weight by day 28, with a clear dose-dependent effect, and the drug was generally well tolerated. As with the entire GLP-1 class, the most common side effects were gastrointestinal — mostly mild nausea and vomiting. These are early, short-term results, but they are real human data, which sets conveglipron apart from the many compounds that exist only on preclinical evidence. ## Where it sits in the oral GLP-1 race Conveglipron is not alone. Eli Lilly's orforglipron is the most advanced oral small-molecule GLP-1, with large Phase 3 obesity and diabetes datasets already reported. Pfizer's danuglipron was a high-profile competitor until Pfizer discontinued its weight-management development. Against that backdrop, conveglipron is a mid-pack but genuinely clinical-stage contender: as of early 2026 it was reported to be in Phase 3 trials for type 2 diabetes and Phase 2 trials for obesity, primarily in China. It joins a broader Chinese obesity-drug wave that also includes biased GLP-1 peptides like ecnoglutide. The key questions for conveglipron are the same ones facing every oral GLP-1: can a pill match the double-digit weight loss of the best injectables, and can it do so with tolerable gastrointestinal effects? ## Small molecule does not mean peptide — and 'in trials' does not mean 'available' Two clarifications are worth stating plainly, both for accurate understanding and because they are frequently muddled online. First, conveglipron acts at the GLP-1 receptor but is a small molecule, not a peptide — the same point that applies to orforglipron and danuglipron. People searching for 'GLP-1 peptides' will encounter it, but it does not belong in the same chemical category as semaglutide. Second, conveglipron is investigational. It is not approved by the FDA, it is not approved for obesity by any regulator, and it is not a marketed, prescribed, or compounded consumer product. A compound being studied by a real pharmaceutical company in registered trials is on a legitimate regulated path — but that is very different from something a consumer can or should obtain. Any product sold online under the name 'conveglipron' or 'HDM1002' should be treated with extreme caution. ## What to watch next The near-term signals to watch for conveglipron are larger and longer Phase 2/3 obesity readouts (especially weight loss at 6–12 months rather than 28 days), head-to-head or cross-trial comparisons against orforglipron, gastrointestinal tolerability and discontinuation rates at effective doses, and whether Huadong pursues regulatory paths beyond China. More broadly, conveglipron is a useful marker of where obesity medicine is heading: away from the assumption that the best drugs must be injected, and toward a competitive field of oral options — small molecules at the GLP-1 receptor like conveglipron and orforglipron, and, increasingly, oral approaches to other mechanisms such as amylin. The injectable era proved the biology; the oral era is now a manufacturing, access, and tolerability contest. Ready to track your peptide research? [Open PepTracker Pro](https://app.peptrackerpro.com) PepTracker Pro Research Team The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges. ## Citations 1. \[1\] Xu et al. — HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo-Controlled, Ascending-Dose Phase 1b Study (Obesity, 2026) [Source](https://onlinelibrary.wiley.com/doi/10.1002/oby.70160) 2. \[2\] Pu J. et al. — First-in-human study of HDM1002, a GLP-1 receptor agonist (Diabetes, Obesity & Metabolism, 2025) [Source](https://doi.org/10.1111/dom.16610) 3. \[3\] Huadong Medicine — Positive Phase I Results for Oral Small Molecule GLP-1 Receptor Agonist HDM1002 (PR Newswire) [Source](https://www.prnewswire.com/news-releases/huadong-medicine-announces-positive-phase-i-results-for-innovative-oral-small-molecule-glp-1-receptor-agonist-hdm1002-302183199.html) 4. \[4\] Conveglipron — drug profile (Wikipedia, citing AdisInsight/EASD) [Source](https://en.wikipedia.org/wiki/Conveglipron) 5. \[5\] Pfizer — Discontinues Development of Danuglipron for Chronic Weight Management [Source](https://www.pharmexec.com/view/pfizer-discontinues-development-danuglipron-chronic-weight-management) **Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. [Read full research disclaimer →](/research-disclaimer) ## Related Articles [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026) Research & Compounds [ ### 'Exercise in a Pill' Goes Mainstream: SLU-PP-332, 5-Amino-1MQ, and MOTS-c — and Why the FDA's July PCAC Vote Won't Cover All of Them — June 12, 2026 ](/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026) A wave of 'exercise mimetic' and mitochondrial metabolic compounds — SLU-PP-332, 5-Amino-1MQ, and MOTS-c — is moving from research-chemical forums into mainstream wellness, with anti-doping labs now building detection assays. But there's a critical distinction buyers miss: only some of these are on the FDA's July 23–24 PCAC compounding review list. We break down the mechanisms, the evidence (almost entirely preclinical), and what the July vote actually changes. PepTracker Pro Team June 12, 2026 9 min read SLU-PP-332exercise mimeticERR agonist [Read](/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026) Research & Compounds [ ### A Peptide That Targeted Visceral Fat — and Improved Sleep — Without Lean-Mass Loss: What the Pep19 Trial Shows, and How It Differs From GLP-1s — June 13, 2026 ](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026) An early human trial of Pep19 — a synthetic intracellular peptide that works through the endocannabinoid system — cut visceral fat by about 17% and improved sleep over 60 days, with no lean-mass loss and no reported side effects. That combination is unusual. Here's what the data actually show, why the endocannabinoid mechanism is both promising and historically fraught, and how Pep19 differs from the GLP-1 and amylin drugs dominating the obesity conversation. PepTracker Pro Team June 13, 2026 9 min read Pep19endocannabinoid peptideendocannabinoid system [Read](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026) Research & Compounds [ ### The Race to Put Amylin in a Pill: ACCG-2671 Enters the Clinic, and How Oral Amylin Stacks Up Against Injectable Amylin and GLP-1 — June 14, 2026 ](/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026) Amylin has become the obesity field's favorite non-GLP-1 mechanism — but almost every amylin drug is an injection. Structure Therapeutics just started first-in-human testing of ACCG-2671, an oral, once-daily small-molecule amylin agonist. Here's what amylin does, why an oral version matters, how ACCG-2671 compares to amycretin, eloralintide, cagrilintide, and petrelintide, and why 'in a Phase 1 trial' is very different from 'available to buy.' PepTracker Pro Team June 14, 2026 9 min read ACCG-2671oral amylinamylin receptor agonist [Read](/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/kai-7535-hrs-7535-hengrui-kailera-oral-small-molecule-glp1-harbor-1-outstand-2-phase3-liver-safety-obesity-august-2-2026) Research & Compounds [ ### KAI-7535: Another Oral GLP-1 Pill Clears Phase 3 — With a Clean Liver-Safety Readout (August 2, 2026) ](/blog/kai-7535-hrs-7535-hengrui-kailera-oral-small-molecule-glp1-harbor-1-outstand-2-phase3-liver-safety-obesity-august-2-2026) The oral GLP-1 pill race just added another late-stage entrant. Hengrui's HRS-7535 — developed outside China by Kailera as KAI-7535 — posted up to 10.9% weight loss at Week 44 in a Chinese Phase 3 obesity trial and beat dapagliflozin on blood sugar in a diabetes trial, with no liver-safety signal. Here is what the data show and where it sits versus orforglipron and aleniglipron. PepTracker Pro Team August 2, 2026 7 min read KAI-7535HRS-7535Kailera [Read](/blog/kai-7535-hrs-7535-hengrui-kailera-oral-small-molecule-glp1-harbor-1-outstand-2-phase3-liver-safety-obesity-august-2-2026) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.